Antibiotic prescription patterns and determinants for influenza-like illness in selected tertiary hospitals in Bangladesh: A WHO AWaRe classification-based analysis
Figures
Abstract
Antibiotics are frequently prescribed for patients with influenza-like illness (ILI), despite their ineffectiveness against viral infections. This study aimed to assess the patterns, trends and factors associated with antibiotic prescriptions for patients with ILI based on the World Health Organization (WHO) AWaRe classification in Bangladesh. This cross-sectional study conducted secondary analysis of data collected through hospital-based influenza surveillance between January 2011 and December 2017, from outpatients who met the WHO ILI case definition. Descriptive statistics assessed prescribing patterns, the Cochran–Armitage test assessed temporal trends, and multivariable logistic regression identified determinants of antibiotic prescriptions. Among 7,041 enrolled patients with ILI [median age: 4 years (IQR: 1.17–20 years), 55.6% male], 84.3% (5,939) received at least one antibiotic. Of them (5,939), 98.3% received a single antibiotic agent, 1.7% received two agents, and 0.03% received more than three agents. The most prescribed antibiotics (N = 6,045) were azithromycin (42.2%), amoxicillin (26.2%), and cefixime (14.9%). Azithromycin (p = 0.015) and cefixime (p = 0.044) increased significantly, while amoxicillin (p = 0.019) and ciprofloxacin (p = 0.039) declined significantly. According to the AWaRe classification, 69% of prescribed antibiotics were from the Watch group, while 31% were from the Access group, and none were from the Reserve group. The prescriptions of Access group declined (p = 0.029), whereas the Watch group increased significantly (p = 0.029). Antibiotic prescriptions were more common among patients aged <5 years (aOR: 1.45; 95% CI: 1.25–1.68), those treated at government hospitals (aOR: 3.76; 95% CI: 3.26–4.35), and those reported history of runny nose (aOR: 1.91; 95% CI: 1.62–2.56) or sore throat (aOR: 1.93; 95% CI: 1.48–2.51). A substantial proportion of patients with ILI received antibiotics, with a notable increase in Watch group antibiotics. These findings underscore the need to strengthen hospital-based antimicrobial stewardship programmes in Bangladesh to promote appropriate antibiotic prescribing and address antimicrobial resistance.
Citation: Bhuiya S, Aleem MA, Shuvo TA, Hassan MZ, Mamun GMS, Khan SY, et al. (2026) Antibiotic prescription patterns and determinants for influenza-like illness in selected tertiary hospitals in Bangladesh: A WHO AWaRe classification-based analysis. PLOS Glob Public Health 6(11): e0007648. https://doi.org/10.1371/journal.pgph.0007648
Editor: Julia Robinson, PLOS: Public Library of Science, UNITED STATES OF AMERICA
Received: April 6, 2026; Accepted: November 2, 2026; Published: November 20, 2026
Copyright: © 2026 Bhuiya et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Based on the recommendation of its Ethical Review Board, the research administration of icddr,b has restricted making the personal information of hospitalised patients publicly available. However, data generated from icddr,b’s electronic medical record can be provided to interested researchers for secondary data analyses upon approval of a data licensing application and agreement by the icddr,b data center committee. The data request may be sent to info@icddrb.org.
Funding: This study was supported by the Centers for Disease Control and Prevention (US-CDC), Atlanta, Georgia, United States of America (Grant No. U01GH002259, awarded to F.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No authors received a salary directly from the funder.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Antimicrobial resistance (AMR) is a major global health crisis, often referred to as a silent pandemic, driven largely by the inappropriate use of antibiotics [1–3]. Moreover, the World Health Organization (WHO) identifies AMR as one of the top ten global health threats, contributing to increased healthcare-associated costs, prolonged hospital stays, and rising mortality rates [1,2]. The burden of AMR is substantial; the estimate indicates that in 2019, over 4.95 million deaths were linked to AMR, with projections suggesting up to 10 million deaths annually by 2050 if current trends continue [1,4,5]. To tackle the burden of AMR, the WHO and other organizations emphasise the urgent need for national and global actions to address the growing AMR crisis [1,6–8].
The burden of AMR is particularly severe in low- and middle-income countries (LMICs), where the inappropriate antibiotic prescribing is common for respiratory infections such as acute bronchitis, rhinosinusitis, pharyngitis, and influenza-like illness (ILI) [9]. Moreover, studies indicate that approximately 70% of antibiotic prescriptions for respiratory infections, including ILI, are inappropriate in LMICs [9]. Several studies also reported that limited public awareness of antibiotics, AMR, and infectious diseases in LMICs often results in pressure from patients on physicians to prescribe antibiotics for rapid symptom relief, thereby contributing to AMR [3,10,11].
To address these concerns, the WHO introduced the AWaRe (Access, Watch, Reserve) classification system in 2017, with subsequent revisions in 2019, 2021, and 2023, to optimise antibiotic use and mitigate the spread of AMR [12–14]. Under the WHO 13th General Programme of Work (GPW), countries were urged to ensure that at least 60% of total antibiotic consumption comes from the Access group by 2023 [11]. As this global target was not achieved by 2013, the United Nations General Assembly (UNGA) on Antimicrobial Resistance (AMR) set a more ambitious goal in 2024, aiming for at least 70% of global antibiotic use to come from the Access group by 2030 [15].
In response, Bangladesh developed a National Action Plan (NAP) to tackle AMR in 2017, in aligned with the WHO’s Global Action Plan to combat AMR [16]. However, implementation of the NAP remains limited in Bangladesh. A study on antibiotic dispensing in pharmacies in Bangladesh reported that over 53% of dispensed antibiotics were from the Watch group [16]. Similarly, a point-prevalence survey on hospitalised patients in Bangladesh showed that 64% of patients were treated with the Watch group of antibiotics [17]. Despite these findings, evidence describing longitudinal patterns of antibiotic prescribing for ILI patients according to the WHO AWaRe classification in Bangladesh remains limited, particularly from hospital-based surveillance data collected before the expansion of national antimicrobial stewardship activities.
This study aimed to estimate the proportion, patterns, trends, and determinants associated with antibiotic prescriptions for treating patients with ILI in line with the WHO AWaRe classification at the outpatient departments (OPDs) of the tertiary-level hospitals in Bangladesh.
Methods
Ethics statement
Study design
We conducted a cross-sectional secondary data analysis using routinely collected data from the prospective, multicentre hospital-based influenza surveillance (HBIS) in Bangladesh, to examine the antibiotic prescribing patterns among patients with ILI.
Data source, study population and study period
Data were collected on prescribed antibiotics to describe the patterns and trends of antibiotics prescribed among patients with ILI from five tertiary-level hospitals (3 government and 2 private hospitals) participated in the HBIS. The study included patients of all age groups who attended the medicine and paediatric OPDs of the participating surveillance hospitals. The study utilised all available ILI surveillance data collected by icddr,b between June 2011 and September 2017. Due to funding constraints, ILI surveillance was discontinued after September 2017; therefore, more recent ILI surveillance data were not available for analysis.
The seven-year dataset was collected using a consistent ILI case definition and standardised surveillance procedures, enabling assessment of antibiotic prescribing patterns and temporal trends across the study period.
Inclusion criteria: Case identification of ILI
Surveillance physicians monitored outpatient visits to the medicine and pediatric departments, and identified individuals who met the WHO ILI case definition. ILI was defined as an acute respiratory infection with measured fever of ≥ 38 C° and cough, with symptom onset within the last 10 days [18]. Patients meeting these criteria at the five selected hospitals were eligible for inclusion into the study.
Data collection on prescribed antibiotics
WHO AWaRe classification of antibiotics
Antibiotic prescriptions were categorised using the WHO AWaRe (Access, Watch, Reserve) classification, introduced in 2017 and updated in 2023 to support antibiotic stewardship, promote appropriate antibiotic use, and address AMR [14]. Although the study period preceded the introduction of AWaRe classification, it was retrospectively applied to all prescribed antibiotics, consistent with WHO recommendations to extend AWaRe beyond the Essential Medicines List to commonly used antibiotics worldwide. This allowed a standardised assessment of antibiotic prescribing patterns by AWaRe category and facilitated comparison of the observed prescribing patterns with the WHO target that at least 60% of antibiotic consumption should come from the Access group [14].
Three AWaRe groups of antibiotics according to WHO
Access group antibiotics (86 antibiotics): These antibiotics are active against a wide range of susceptible pathogens showing lower resistance potential than antibiotics in the Watch and Reserve groups. Selected Access group antibiotics are recommended as essential first or second-choice empirical treatment options. Antibiotics in this group includes Amikacin, Amoxicillin, Amoxicillin/clavulanic Acid, Ampicillin, Ampicillin/ sulbactam, Metronidazole, Chloramphenicol, Clindamycin, Gentamicin, Cefradine, Flucloxacillin, etc [14].
Watch group antibiotics (140 antibiotics): These antibiotics have higher resistance potential and includes most of the highest-priority agents. Selected Watch group antibiotics are recommended as essential first or second-choice empiric treatment options for a limited number of specific infectious syndromes. Antibiotics in this group includes Azithromycin, Cefaclor, Cefdinir, Cefepime, Cefixime, Cefotaxime, Ceftriaxone, Cefuroxime, Ciprofloxacin, Clarithromycin, etc [14].
Reserve group antibiotics (29 antibiotics): This group includes antibiotics and antibiotic classes that should be reserved for treatment of confirmed or suspected infections caused by multi-drug-resistant organisms. Reserve group antibiotics should be treated as “last resort” options. Antibiotics in this group includes Aztreonam, Colistin, Linezolid, Polymyxin B, Meropenem-vaborbactam, etc [14].
Major exploratory variable
We considered a patient aged <5 years to have at least one danger sign if they had at least one of the following signs or symptoms: chest indrawing, vomiting, inability to drink, stridor, or lethargy. We considered a patient to have at least one comorbid condition if they had at least one of the following conditions: lung disease, asthma, heart disease, chronic obstructive pulmonary disease (COPD), diabetes, hypertension, liver disease, or kidney disease. Age was categorised into five groups: 0– < 5 years, 5–14 years, 15–49 years, 50–59 years, and ≥60 years. The mean and standard deviation (SD) were used to summarise the duration of symptoms before the OPDs visit because the variable was normally distributed. In contrast, age was summarised using the median and interquartile range (IQR) because of its non-symmetrical distribution.
Statistical analysis
Descriptive analysis was conducted to characterise antibiotic prescribing pattern. Antibiotics were categorised according to their generic names, antibiotic class, and WHO AWaRe classification. To identify the most commonly prescribed antibiotic, we used the Drug Utilisation (DU)90% index [16,19]. The drug utilisation 90% (DU90%) index was calculated to identify the number of antibiotics contributing to 90% of the total antibiotics prescribed. To examine associations between categorical variables, the chi-square (χ²) test was employed. The Cochran–Armitage test for trend analysis was used to evaluate temporal trends in antibiotic prescriptions, with statistical significance set at p-value ≤ 0.05. For each antibiotic, we calculated the annual proportion of prescriptions according to generic name and reported the Z statistics and p-value (S1 Table), and we followed the same procedure for antibiotic prescribed according to antibiotic class (S2 Table) and for AWaRe class (S3 Table).
Unadjusted logistic regression analyses were performed to estimate crude odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for each potential predictor associated with antibiotic prescribing. Variables associated with the outcome at p < 0.05 were considered for inclusion in the subsequent regression models (S4 Table). Three separate multivariable logistic regression models were developed to identify factors independently associated with (Model 1) overall antibiotic prescription, (Model 2) prescription of Access group antibiotics, and (Model 3) prescription of Watch group antibiotics. Potential confounders and other covariates, including age, sex, location, health conditions, department, and hospital type, were considered in the models. Multicollinearity was assessed using variance inflation factors (VIFs), with VIF < 5 considered indicative of no substantial multicollinearity (S5 Table). Results are presented as adjusted odds ratios (aORs) with 95% CIs. Statistical significance was defined as a two-sided p-value ≤0.05.
All analyses were conducted using Stata version 15.0 (StataCorp, 2017).
Results
Demographic and clinical characteristics of patients with ILI
From June 2011 to September 2017, a total of 7,041 patients with ILI were enrolled from the OPDs of the five selected hospitals (Table 1). The median age of the enrolled patients was 4 years (IQR: 1.17–20 years), and 55.6% (3,919) were male. The mean time between symptom onset and the OPDs visit was 3 days (±1.4). In addition to the signs and symptoms included in the ILI case definition (i.e., cough and fever), the most commonly reported symptoms across all age groups were runny nose 84.6% (5,956), and difficulty breathing 25.1% (1,767) (Table 1). Among patients aged <5 years (24.6%; 1,729), the most commonly reported symptoms were chest indrawing (6.1%; 105), vomiting (8.8%; 152), and inability to drink (1.5%; 26).
Antibiotics prescribed to treat patients with ILI, by age group
Among all the patients with ILI, 84.3% (5,939/7,041) received a total of 6,045 antibiotic agents. Of these patients, 2.0% (104) were prescribed ≥ 2 antibiotic agents.
When stratified into two age groups (aged <5 years and aged ≥5 years), 86.2% (3,138/ 3,639) of patients aged <5 years were prescribed antibiotics. Of them 1.6% (42) prescribed ≥2 antibiotic agents. Among patients aged ≥5 years, 82.3% (2,801/3,402) were prescribed antibiotics. Of them, 2.2% (62) prescribed ≥2 antibiotic agents. The proportion of patients prescribed antibiotics was significantly higher among those aged <5 years than among those aged ≥5 years (86.2% vs. 82.3%, p < 0.001). Among the five age groups (<5 year, 5–14 years, 15–49 years, 50–59 years, 60 years & above), 86% patients aged <5 were received antibiotics, 84.5% among aged 5–14 years, 81.1% among aged 15–49 years, 82.0% among 50–60 years and 81.3% among ≥60 years (p < 0.001). among all the age groups, more that 97% of patients who received antibiotics were prescribed one antibiotic agent (Fig 1).
Pattern of antibiotics prescribed according to generic name and AWaRe classification
The most frequently prescribed antibiotics were azithromycin (42.2%; 2,552), followed by amoxicillin (26.2%; 1,583), cefixime (14.9%; 900), ceftriaxone (2.8%; 170), ciprofloxacin (2.3%; 140) and levofloxacin (2.2%; 131). These six antibiotics accounted for 90.6% of total drug use (DU 90%) (Table 2). A total of 31 different antibiotics were prescribed to treat patients with ILI. Of these, 17 antibiotics belonged to the Access group, accounting for 31.1% (1,882/6,045) of all antibiotic prescriptions, while the remaining 14 antibiotics were from the Watch group, making up 69% (4,163/6,045) of the total prescriptions. (Table 2).
Trend of prescribed antibiotics according to generic name
Significant upward trends were observed in the prescription of azithromycin, which increased from 33.9% in 2013 to 56.1% in 2015 (p = 0.015), and cefixime, which increased from 8.5% in 2011 to 26.8% in 2017 (p = 0.044) (Fig 2). Cnversely, amoxicillin prescriptions declined significantly, from 41.6% in 2011 to 2.7% in 2017 (p = 0.019). Ciprofloxacin prescriptions also declined, from 3.8% to 1.0% (p = 0.039). No statistically significant trends were observed in the prescription of ceftriaxone, levofloxacin, and cephradine over the study period.
Antibiotics prescribed by antibiotic class
Five antibiotic classes accounted for 95.7% of all antibiotic prescription. The most frequently prescribed classes were macrolides (42.5%;2,568) followed by penicillins (27.1%;1640), third-generation cephalosporins (20.1%;1214), fluoroquinolones (4.6%; 275), and first-generation cephalosporins (1.4%;87) (Fig 3).
Trend in antibiotic prescriptions by antibiotic class
During the study period, the prescription of macrolides showed a significantly upward trend, increasing from 31.7% in 2011 to 58.4% in 2017 (p = 0.016). In contrast, penicillins prescription showed a marked decline, decreasing from 42.4% to 3.6% (p = 0.023) during the study period (Fig 4). Although an upward trend in the prescription of third-generation cephalosporin were observed from 2014 onward, no statistically significant trends, either upward or downward, were observed for third-generation cephalosporins, fluoroquinolones, or first-generation cephalosporins.
Antibiotics prescriptions by age group according to the WHO AWaRe classification
Of the 6,045 antibiotic agents prescribed, 69.0% (4163/6,045) belong to Watch group and only 31.0% (1,882/6,045) belong to Access group, while none of these antibiotics belong to Reserve group of antibiotics. The proportion of Access group antibiotics prescribed was higher among patients aged <5 years than among those aged ≥5 years (37.8% vs. 23.8%, p < 0.001). In contrast, the proportion of Watch group antibiotics prescribed was lower among patients aged <5 years than among those aged ≥5 years (62.2% vs. 76.2%; p < 0.001) (Fig 5).
Trends in antibiotic prescriptions according to the WHO AWaRe classification
During the study period, the proportion of Watch group antibiotics prescribed to treat patients with ILI increased from 54.3% in 2011 to 94.6% in 2017, with a sharp increase from 52.7% in 2013 to 89.5% in 2015 (p = 0.029). In contrast, the proportion of Access group antibiotics prescribed decreased from 45.7% in 2011 to 5.4% in 2017 (p = 0.029) (Fig 6).
Factors associated with antibiotic prescription to treat patients with ILI
Overall antibiotic use: In the univariable analysis, male patients had lower odds of receiving antibiotics than female patients (OR: 0.67; 95% CI: 0.59–0.76; p < 0.001). Children aged <5 years had higher odds of receiving antibiotics than patients aged ≥5 years (OR: 1.34; 95% CI: 1.18–1.53; p < 0.001). The odds of antibiotic prescription were substantially higher among patients treated at government hospitals than among those treated at private hospitals (OR: 4.01; 95% CI: 3.51–4.58; p < 0.001). Several clinical characteristics were also associated with antibiotic prescribing. Patients presenting with difficulty breathing had higher odds of receiving antibiotics than those without this symptom (OR: 1.39; 95% CI: 1.19–1.62; p < 0.001). Similarly, patients with a history of runny nose had more than twice the odds of receiving antibiotics compared with those without a runny nose (OR: 2.54; 95% CI: 2.18–2.95; p < 0.001). A history of sore throat was also associated with higher odds of antibiotic prescription (OR: 1.75; 95% CI: 1.37–2.23; p < 0.001). In contrast, patients with at least one comorbid condition had lower odds of receiving antibiotics than those without any comorbidity (OR: 0.43; 95% CI: 0.28–0.66; p < 0.001). Additionally, patients admitted ≥3 days after symptom onset had higher odds of receiving antibiotics than those admitted within 3 days of symptom onset (OR: 1.16; 95% CI: 1.02–1.32; p = 0.025).
In the multivariable analysis, after adjustment for potential confounders, patients treated at government hospitals had higher odds of receiving antibiotics than those treated at private hospitals (aOR: 3.76; 95% CI: 3.26–4.35; p < 0.001) (Table 3). Children aged <5 years also had higher odds of receiving antibiotics than patients aged ≥5 years (aOR: 1.45; 95% CI: 1.25–1.68; p < 0.001). Clinical presentation was significantly associated with antibiotic prescribing. Patients presenting with a history of runny nose had higher odds of receiving antibiotics than those without this symptom (aOR: 1.91; 95% CI: 1.62–2.56; p < 0.001). Likewise, patients reporting a sore throat had higher odds of being prescribed antibiotics than those without a sore throat (aOR: 1.93; 95% CI: 1.48–2.51; p < 0.001) (Table 3).
Access group antibiotics: In the univariable logistic regression analysis, male patients had lower odds of receiving an Access group antibiotic than female patients (OR: 0.84; 95% CI: 0.76–0.94; p = 0.002). Patients aged <5 years had higher odds of receiving an Access group antibiotic than those aged ≥5 years (OR: 1.96; 95% CI: 1.76–2.19; p < 0.001). Patients treated at government hospitals had higher odds of receiving an Access group antibiotic than those treated at private hospitals (OR: 3.83; 95% CI: 3.33–4.41; p < 0.001). Similarly, a history of difficulty breathing (OR: 2.04; 95% CI: 1.82–2.29; p < 0.001) and a history of runny nose (OR: 2.58; 95% CI: 2.15–3.10; p < 0.001) were associated with higher odds of receiving an Access group antibiotic. Conversely, having at least one comorbid condition (OR: 0.49; 95% CI: 0.28–0.84; p = 0.010) and symptom duration of ≥3 days before admission (OR: 0.76; 95% CI: 0.68–0.84; p < 0.001) were associated with lower odds of receiving an Access group antibiotic. A history of sore throat was not significantly associated with receiving an Access group antibiotic (OR: 0.84; 95% CI: 0.71–1.01; p = 0.059).
After adjustment for potential confounders, children aged <5 years had 82% higher odds of receiving an Access group antibiotic than those aged ≥5 years (aOR: 1.82; 95% CI: 1.61–2.05; p < 0.001). Treatment at a government hospital remained strongly associated with Access group antibiotic prescription (aOR: 3.93; 95% CI: 3.38–4.57; p < 0.001). A history of difficulty breathing (aOR: 1.53; 95% CI: 1.35–1.73; p < 0.001) and a history of runny nose (aOR: 1.77; 95% CI: 1.46–2.15; p < 0.001) also associated with higher odds of receiving an Access group antibiotic (Table 3).
Watch group antibiotics: In the univariable analysis, age < 5 years (OR: 0.67; 95% CI: 0.61–0.74; p < 0.001) and a history of difficulty breathing (OR: 0.64; 95% CI: 0.57–0.71; p < 0.001) were associated with lower odds of receiving a Watch group antibiotic. In contrast, a history of sore throat (OR: 1.51; 95% CI: 1.29–1.77; p < 0.001) and symptom duration of ≥3 days before admission (OR: 1.38; 95% CI: 1.25–1.52; p < 0.001) were associated with higher odds of receiving a Watch group antibiotic (Table 3).
After adjustment for potential confounders, age < 5 years remained independently associated with lower odds of receiving a Watch group antibiotic than age ≥ 5 years (aOR: 0.76; 95% CI: 0.69–0.84; p < 0.001). Similarly, patients with a history of difficulty breathing had lower odds of receiving a Watch group antibiotic than those without such a history (aOR: 0.65; 95% CI: 0.59–0.73; p < 0.001). Conversely, a history of sore throat remained significantly associated with higher odds of receiving a Watch group antibiotic (aOR: 1.21; 95% CI: 1.02–1.44; p = 0.027). Patients admitted ≥3 days after symptom onset had higher odds of receiving a Watch group antibiotic than those admitted within 3 days of symptom onset (aOR: 1.35; 95% CI: 1.23–1.50; p < 0.001) (Table 3).
Discussion
This study revealed a high rate of antibiotic prescribing (84.3%) among patients with ILI during their OPDs visit, with almost 2% receiving multiple antibiotic agents. Our findings are consistent with antibiotic prescribing rates reported among patients with ILI in rural Thailand during 2003–2004 and among patients with ARI in China during 2017–2018 (both 86%), but lower than the 97% reported among ARI patients in Vietnamese during 2019 in primary care settings [10,20,21]. However, a study conducted in Bangladesh during 2017–2022 among patients with severe acute respiratory infection (SARI) reported a higher prevalence of antibiotic prescribing (88%) than that observe in our study, possibly reflecting the greater severity of illness among patients with SARI [22]. To promote judicious antibiotic use and combat AMR, lessons from assertive antibiotic stewardship campaigns implemented in the USA could inform strategies in Bangladesh and other LMICs [23]. Expanding the availability of point-of-care testing for a broader range of respiratory viruses may help to reduce inappropriate antibiotic prescribing [24–26]. However, access to such diagnostic resources remains limited in Bangladesh and many other LMICs, presenting a barrier to improving antibiotic stewardship.
Our study also found that antibiotic prescribing was significantly higher among children <5 years (86%) than among patients aged ≥5 years (82%). Similar findings have been reported in studies from the USA among ILI patients during 2010–2014 and Gambia among patients with ILI during 2018, where pediatric patients were more likely to receive antibiotics than adults [27,28]. The higher prescribing rates among young children may be influenced by their increased vulnerability to infections, parental pressure, and a cautious approach by healthcare providers [29,30]. To address these challenges, comprehensive antibiotic stewardship programmes should be implemented. Such programmes should include educational initiatives targeting healthcare providers, patients and caregivers to promote evidence-based prescribing practices and reduce unnecessary antibiotic use [31].
We found that, penicillin (generic name: amoxycillin) was the 2nd most frequently prescribed antibiotics, which was generally prescribed as a first line treatment of pneumonia according to guidelines for the management of pneumonia [32]. Nevertheless, extensive and inappropriate use of penicillin may accelerate the development of AMR among circulating pathogens [33]. As susceptibility to penicillin declines, clinicians may undermine the effectiveness of first-line treatment options and increasingly rely on broader-spectrum antibiotics from macrolides class, such as azithromycin [34]. Additionally, our findings revealed that macrolides (n = 2568), of which 99% were azithromycin, a watch group antibiotic, were the most frequently prescribed class of antibiotics among patients with ILI. This finding was broadly consistent with a study conducted in OPDs in China, where it reported as the third most used antibiotics [21]. Our findings differ from many other countries, including India, where macrolides do not rank among the top five prescribed antibiotics among inpatients in 2019 due to different patients’ inclusion criteria [35,36]. Moreover, the significant increase in macrolides prescribing may be partly related to their use for bacterial infections, including community-acquired pneumonia [32,37]. In addition, azithromycin uses also increased substantially during the study period, possibly because of its perceived effectiveness against a broad range of respiratory pathogens, including atypical bacteria, convenient once-daily, widespread availability and frequent use as empirical therapy for respiratory and febrile illnesses [37–39]. In addition, azithromycin is manufactured by almost every pharmaceutical companies in Bangladesh, making it widely available and relatively affordable [40].
This prescribing pattern raises concerns about the potential consequences of excessive macrolide use, particularly azithromycin a broader-spectrum antibiotic, antimicrobial susceptibility among respiratory pathogens such as Streptococcus pneumoniae [36,41,42]. As resistance increases, the clinical effectiveness of macrolides may decline, potentially limiting treatment options for respiratory tract infections and other bacterial diseases [43]. Moreover, the high frequency of third-generation cephalosporins (n = 1214, where 74% were cefixime and 14% with ceftriaxone along with cefpodoxime, cefotaxime, ceftazidime all belong to Watch category) prescription is also concerning, as these antibiotics are known contributors to the rise of extended-spectrum beta-lactamase producing pathogens [44,45].
Our study also identified a significant upward trend in macrolide prescriptions, while penicillin prescription showed a downward trend. Interestingly, a reverse trend has been observed in France among patients with ILI during 2004–2018, where penicillin prescriptions have increased while macrolide use has declined [46]. These differences may be attributed to variations in socio-demographic characteristics, healthcare policies, study period, and public awareness of AMR in these two study settings. Further research is needed to understand the drivers of these prescribing patterns and to develop targeted interventions to promote more rational antibiotic use.
Moreover, our data revealed that the majority of patients with ILI (69%) were treated with Watch group antibiotics, while none received Reserve group antibiotics. This finding is consistent with a study in Bangladesh among hospitalised patients during 2021, which reported that 64% of prescribed antibiotics belonged to the Watch group [17]. Similarly, a point prevalence survey conducted in India among hospitalised patients during 2019 found a higher consumption of Watch group antibiotics (57.9%) [35]. A global survey further highlighted that Watch antibiotic prescriptions were more common in West and Central Asia, Eastern Europe, Latin and North America, whereas Access antibiotics were more frequently used in Oceania, Northern Africa, and sub-Saharan Africa [36]. Mirroring to our findings, several countries have reported no prescriptions of Reserve group antibiotics [36]. The extensive use of Watch group antibiotics, particularly broad-spectrum agents, is concerning because it may accelerate the development of AMR and multidrug resistance (MDR) organisms [47]. Such antibiotics can disrupt gut microbiota by reducing microbial diversity and depleting beneficial commensal bacteria, potentially increase susceptibility to adverse clinical outcomes [48]. Their widespread use may also contributed to reduce future treatment effectiveness by promoting the selection and spread of MDR organisms and hard-to-treat infection [47]. In addition, evidence shows that antibiotic exposure can increase the abundance and dissemination of resistance genes within the gut microbiome, including among individuals not directly exposed to antibiotics, through horizontal gene transfer and community-level transmission dynamics [49]. The high use of Watch group antibiotics in Bangladesh may be driven by pharmaceutical supply trends, as a significant proportion of antibiotics supplied by pharmaceutical companies belong to Watch category [50].
To minimise the risk of AMR, the UNGA on AMR set a target for at least 70% of overall antibiotic use to come from the Access group; however, our findings showed that only 31% of prescribed antibiotics belonged to the Access group, while 69% belonged to the Watch group, which is an alarming trend [15]. Notably, in 2017, 94.6% of prescribed antibiotics belonged to the Watch group, while only 5.4% were from the Access group, representing the lowest proportion of Access group antibiotic use during the study period. The increasing reliance on Watch antibiotics, which carry a higher resistance risk, raises concerns about the adequacy of first-line treatment options. Similar prescribing patterns in other LMICs emphasise the need for strengthened antimicrobial stewardship, updated treatment guidelines, and enhanced surveillance systems [51]. Conversely, the absence of Reserve group antibiotic prescriptions was expected because these agents are generally reserved for severe infections caused by MDR bacterial and are not routinely indicated for outpatient management of patients with ILI. These findings underscore the need to reassess prescribing practices to balance effective treatment and resistance mitigation.
Data showed that patients treated in government hospitals were more likely to receive antibiotics than those treated in private hospitals, which is consistent with findings from a study conducted in Bangladesh among children <5 years with acute respiratory infection (ARI) [52]. Furthermore, we found that prolonged duration of symptoms before admission was associated with an increased probability of antibiotic prescribing, aligning with results from a study on ARI patients in the United States [53]. Our analysis also revealed that children were more likely to be prescribed both group of antibiotic (the Watch group antibiotics as well as Access group of antibiotics) than those of adults, reflecting a similar pattern observed among ARI patients in Vietnam [10]. Watch group antibiotic prescriptions were more common among patients with at least one comorbid condition compared to those without comorbidities, consistent with findings from a study conducted on SARI patients in Bangladesh [47].
Addressing AMR requires a multifaceted and comprehensive approach that includes policy development, healthcare training, and continuous monitoring. As highlighted in previous research, key strategies include the establishment of national treatment guidelines, structured training programmes for healthcare professionals, and routine audits to ensure compliance with antibiotic stewardship policies [54]. These measures help standardise prescribing practices, minimise inappropriate antibiotic use, and promote adherence to evidence-based guidelines. Several countries have successfully implemented initiatives to align antibiotic usage with national and global AMR control strategies. In England, for instance, a programme was implemented to synchronise the national Essential Medicines List with their antibiotic stewardship policies [55]. This initiative resulted in a significant increase in the prescription of Access group antibiotics, which are recommended as first-line treatments due to their lower resistance potential [56]. The integration of national medicine policies with stewardship programmes ensures that healthcare providers receive clear guidance on appropriate antibiotic prescribing while prioritising drugs with lower resistance risks. Similarly, in sub-Saharan Africa, an Antimicrobial Stewardship Programme was specifically designed to address region-specific AMR challenges. The programme led to notable improvements in prescribing practices, increased awareness of AMR among healthcare professionals, and better adherence to treatment guidelines [57]. The success of this initiatives underscores the importance of context-specific interventions that consider local prescribing behaviours, healthcare infrastructure, and disease burden. Given the complexity of AMR, a “Whole-System Approach” has been proposed as a more effective strategy to combat antibiotic resistance [3]. This approach integrates multiple components of the healthcare system, ensuring a coordinated effort among governments, healthcare providers, and public health organisations to optimise antibiotic prescription and mitigate resistance on a broader scale. By implementing such comprehensive strategies, countries can work toward more sustainable and effective AMR management. Moreover, data-driven matrics alone are insufficient to understand antibiotic use or AMR in southeast Asia; these challenges must be understood and tackled as a “syndemic phenomenon” - arising from interacting, co-present, or sequential diseases shaped by the social, cultural, political economy and environmental conditions that promote and intensify resistance [58].
This study has several limitations. It relies on secondary data from the HBIS collected at OPDs, which may lack critical clinical and prescription details, such as physicians’ rationale for prescribing antibiotics and laboratory-confirmed bacterial infections. The absence of microbiological data makes it difficult to determine whether antibiotics were clinically justified, especially since ILI is primarily viral in nature. Bangladesh introduced regulatory and antimicrobial stewardship measures mostly after 2017 [59,60], and the prescribing patterns observed in this study (2011–2017) largely reflect a period preceding the implementation of these initiatives and therefore provide a historical baseline for future comparisons. In particular, the predominance of Watch group antibiotics and the declining use of Access group antibiotics observed during this period may provide useful benchmarks for assessing whether prescribing patterns have changed following subsequent stewardship efforts. However, as ILI surveillance was discontinued after 2017, the study cannot assess changes in prescribing during or after the COVID-19 pandemic or determine the impact of subsequent antimicrobial stewardship policies in Bangladesh. The findings should therefore not be interpreted as representative of current antibiotic prescribing practices in Bangladesh. Contemporary surveillance using comparable methods is needed to determine whether antibiotic prescribing among patients with ILI has changed and to assess the impact of subsequent antimicrobial stewardship efforts. Moreover, the study lacks data on AMR patterns, which would have provided insights into resistance trends among the most prescribed antibiotics. Data were collected from only five tertiary-level hospitals, three of which were government facilities, limiting the generalisability of the findings to other healthcare settings, such as private clinics, pharmacies, or rural healthcare centres, where prescribing behaviours may differ. Additionally, data on self-medication prior to OPDs visit were not collected, limiting our ability to assess the potential contribution of self-medication to antibiotic use during OPDs visit. The study also lacks key confounding factors, such as disease severity and patient anthropometric data, which are important for associative model.
Conclusion
More than eight in ten patients with ILI were prescribed antibiotics during OPDs visit, with Watch group antibiotics predominating, particularly among children. This finding raises concerns about inappropriate antibiotic prescribing in Bangladesh. Moreover, the increasing use of Watch group antibiotics underscores the importance of promoting appropriate use of Access group antibiotics to tackle AMR. Our study findings highlight the need for a national antimicrobial stewardship programme for physicians, including the development and implementation of local guidelines, in-service training on rational antibiotic prescription with an emphasis on WHO AWaRe Classification, and enhanced awareness of AMR and strengthened enforcement of relevant regulations. A co-design approach involving key stakeholders could support the development and implementation of context-specific antimicrobial stewardship interventions.
Supporting information
S1 Table. Cochran–Armitage trend analysis was used to evaluate temporal trends in antibiotic prescriptions according to generic name.
https://doi.org/10.1371/journal.pgph.0007648.s001
(DOCX)
S2 Table. Cochran–Armitage trend analysis was used to evaluate temporal trends in antibiotic prescriptions according to antibiotic class.
https://doi.org/10.1371/journal.pgph.0007648.s002
(DOCX)
S3 Table. Cochran–Armitage trend analysis was used to evaluate temporal trends in antibiotic prescriptions according to AWaRe class.
https://doi.org/10.1371/journal.pgph.0007648.s003
(DOCX)
S4 Table. Bivariate analysis performed to identify potential factors for regression analysis.
https://doi.org/10.1371/journal.pgph.0007648.s004
(DOCX)
S5 Table. Identify individual and model variance inflation factors (VIF).
https://doi.org/10.1371/journal.pgph.0007648.s005
(DOCX)
Acknowledgments
We acknowledge surveillance physicians, collaborators at the hospitals, and field staff for their continuous support. We are grateful to the study participants for their time. icddr,b is grateful to the Governments of Bangladesh and Canada for providing core/unrestricted support. We sincerely thank the reviewers for their time, valuable feedback, and constructive suggestions, which helped improve the quality this manuscript, and strengthen the arguments.
Declaration of generative AI and AI-assisted technologies in the writing process: During the preparation of this work, we used Grammarly AI to assist with grammar checking and language refinement. After using this tool, we thoroughly reviewed and edited the content as needed and take full responsibility for the final content of the publication.
References
- 1.
World Health Organization. Antimicrobial resistance Zeneva: World Health Organization; 2023. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
- 2. Sihombing B, Bhatia R, Srivastava R, Aditama TY, Laxminarayan R, Rijal S. Response to antimicrobial resistance in South-East Asia Region. Lancet Reg Health Southeast Asia. 2023;18:100306. pmid:38028162
- 3. Goldmann D, Rajan S, Udayakumar K. Preventing and controlling global antimicrobial resistance - implementing a whole-system approach. N Engl J Med. 2024;391(8):681–5. pmid:39158136
- 4. de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050?. PLoS Med. 2016;13(11):e1002184. pmid:27898664
- 5. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet. 2022;399(10325):629–55. pmid:35065702
- 6.
Prevention C. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: U.S. Department of Health and Human Services; 2013. https://www.cdc.gov/antimicrobial-resistance/media/pdfs/ar-threats-2013-508.pdf
- 7. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309–18. pmid:26343252
- 8.
World Health Organization. Global action plan on antimicrobial resistance. Geneva, Switzerland: WHO; 2015. https://iris.who.int/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1
- 9.
Centers for Disease Control and Prevention (CDC). Be Antibiotics Aware is a national effort to help fight antibiotic resistance and improve antibiotic prescribing and use: Division of Healthcare Quality Promotion (DHQP), USA; 2023. https://www.cdc.gov/antibiotic-use/index.html
- 10. Nguyen NV, Do NTT, Vu DTV, Greer RC, Dittrich S, Vandendorpe M, et al. Outpatient antibiotic prescribing for acute respiratory infections in Vietnamese primary care settings by the WHO AWaRe (Access, Watch and Reserve) classification: An analysis using routinely collected electronic prescription data. Lancet Reg Health West Pac. 2022;30:100611. pmid:36419738
- 11. Hossain MJ, Jabin N, Ahmmed F, Sultana A, Abdur Rahman SM, Islam MR. Irrational use of antibiotics and factors associated with antibiotic resistance: Findings from a cross-sectional study in Bangladesh. Health Sci Rep. 2023;6(8):e1465. pmid:37520458
- 12.
World Health Organization. WHO releases the 2019 AWaRe Classification Antibiotics Geneva, Switzerland: World Health Organization; 2019. https://www.who.int/news/item/01-10-2019-who-releases-the-2019-aware-classification-antibiotics
- 13.
World Health Organization. WHO access, watch, reserve, classification of antibiotics for evaluation and monitoring of use Geneva, Switzerland: World Health Organization; 2021. https://www.who.int/publications/i/item/2021-aware-classification
- 14.
World Health Organization. AWaRe classification of antibiotics for evaluation and monitoring of use, 2023. Geneva, Switzerland: World Health Organization; 2023. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04
- 15.
United Nations. Political Declaration of the High-level Meeting on Antimicrobial Resistance New York City, United States: United Nations,; 2024.https://www.un.org/pga/wp-content/uploads/sites/108/2024/09/FINAL-Text-AMR-to-PGA.pdf
- 16. Islam MA, Akhtar Z, Hassan MZ, Chowdhury S, Rashid MM, Aleem MA, et al. Pattern of Antibiotic Dispensing at Pharmacies According to the WHO Access, Watch, Reserve (AWaRe) Classification in Bangladesh. Antibiotics (Basel). 2022;11(2):247. pmid:35203851
- 17. Rashid MM, Akhtar Z, Chowdhury S, Islam MA, Parveen S, Ghosh PK, et al. Pattern of Antibiotic Use among Hospitalized Patients according to WHO Access, Watch, Reserve (AWaRe) Classification: Findings from a Point Prevalence Survey in Bangladesh. Antibiotics (Basel). 2022;11(6):810. pmid:35740216
- 18.
World Health Organization. Global Influenza Programme; Surveillance & monitoring Geneva: World Health Organization; 2014.https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring
- 19. Bergman U, Popa C, Tomson Y, Wettermark B, Einarson TR, Aberg H. Drug utilization 90%--a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol. 1998;54(2):113–8. pmid:9626914
- 20. Bhavnani D, Phatinawin L, Chantra S, Olsen SJ, Simmerman JM. The influence of rapid influenza diagnostic testing on antibiotic prescribing patterns in rural Thailand. Int J Infect Dis. 2007;11(4):355–9. pmid:17324602
- 21. Wang J, Li F, Chen Z, Guo Y, Liu N, Liu B, et al. Antibiotic prescription patterns for acute respiratory infections in rural primary healthcare settings in Guangdong, China: Analysis of 162,742 outpatient prescriptions. Antibiotics (Basel). 2023;12(2). pmid:36830207
- 22. Islam MA, Hassan MdZ, Aleem MA, Akhtar Z, Shuvo TA, Ahmmed MK, et al. Antibiotic use among SARI patients according to the AWaRe classification before and during the COVID-19 pandemic in Bangladesh. ASHE. 2023;3(S2):s28–s28.
- 23. Schwartz B. Preventing the spread of antimicrobial resistance among bacterial respiratory pathogens in industrialized countries: The case for judicious antimicrobial use. Clin Infect Dis. 1999;28(2):211–3. pmid:10064228
- 24. Zhang Z, Ma P, Ahmed R, Wang J, Akin D, Soto F, et al. Advanced point-of-care testing technologies for human acute respiratory virus detection. Adv Mater. 2022;34(1):e2103646. pmid:34623709
- 25. Stamm BD, Tamerius J, Reddy S, Barlow S, Hamer C, Kempken A, et al. The influence of rapid influenza diagnostic testing on clinician decision-making for patients with acute respiratory infection in urgent care. Clin Infect Dis. 2023;76(11):1942–8. pmid:36723863
- 26. Jian MJ, Chung HY, Chang CK, Lin JC, Yeh KM, Chen CW. Clinical comparison of three sample-to-answer systems for detecting SARS-CoV-2 in B.1.1.7 lineage emergence. Infect Drug Resist. 2021;14:3255–61. pmid:34429623
- 27. Fairchok M, Chen WJ, Schofield C, Lalani T, Danaher P, Arnold J. Antibiotic prescription patterns related to influenza-like infection. Open Forum Infectious Diseases. Oxford University Press. 2016.
- 28. Jarju S, Greenhalgh K, Wathuo M, Banda M, Camara B, Mendy S, et al. Viral etiology, clinical features and antibiotic use in children <5 Years of age in the gambia presenting with influenza-like Illness. Pediatr Infect Dis J. 2020;39(10):925–30. pmid:32453201
- 29. Nguyen NV, Do NTT, Nguyen CTK, Tran TK, Ho PD, Nguyen HH, et al. Community-level consumption of antibiotics according to the AWaRe (Access, Watch, Reserve) classification in rural Vietnam. JAC Antimicrob Resist. 2020;2(3):dlaa048. pmid:32974610
- 30. Lucas PJ, Cabral C, Hay AD, Horwood J. A systematic review of parent and clinician views and perceptions that influence prescribing decisions in relation to acute childhood infections in primary care. Scand J Prim Health Care. 2015;33(1):11–20. pmid:25716427
- 31. Appiah B, Anum-Hagin D, Gyansa-Luterrodt M, Samman E, Agyeman FKA, Appiah G, et al. Children against antibiotics misuse and antimicrobial resistance: Assessing effectiveness of storytelling and picture drawing as public engagement approaches. Wellcome Open Res. 2021;6:202. pmid:34746442
- 32.
World Health Organization. Pocket book of hospital care for children. Geneva: World Health Organization; 2013. https://iris.who.int/server/api/core/bitstreams/8f110da0-22e6-4ef1-90e4-c9f1b7daa363/content
- 33. Goldstein FW. Penicillin-resistant Streptococcus pneumoniae: Selection by both beta-lactam and non-beta-lactam antibiotics. J Antimicrob Chemother. 1999;44(2):141–4. pmid:10473219
- 34.
One Health Trust. ResistanceMap: Antibiotic resistance 2026. https://resistancemap.onehealthtrust.org/AntibioticResistance.php
- 35. Panditrao AM, Shafiq N, Chatterjee S, Pathak A, Trivedi N, Sadasivam B, et al. A multicentre point prevalence survey (PPS) of antimicrobial use amongst admitted patients in tertiary care centres in India. J Antimicrob Chemother. 2021;76(4):1094–101. pmid:34244744
- 36. Pauwels I, Versporten A, Drapier N, Vlieghe E, Goossens H, Global-PPS network. Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): Results from a worldwide point prevalence survey in 69 countries. J Antimicrob Chemother. 2021;76(6):1614–24. pmid:33822971
- 37.
Sandman Z, Iqbal OA. Azithromycin. Treasure Island (FL): StatPearls Publishing; 2026.
- 38. Yesmin SMS, Chakma P, Habiba U, Rhod Larsen A, Tino Fusire T, Wangmo S, et al. Human antimicrobial use in Bangladesh: Five-year trend analysis including COVID-19 Pandemic Era. Antibiotics (Basel). 2025;14(9):868. pmid:41009847
- 39. Hoque R, Ahmed SM, Naher N, Islam MA, Rousham EK, Islam BZ, et al. Tackling antimicrobial resistance in Bangladesh: A scoping review of policy and practice in human, animal and environment sectors. PLoS One. 2020;15(1):e0227947. pmid:31986167
- 40.
MedEx. Azithromycin Dihydrate Available Brand. 2026.https://medex.com.bd/generics/100/azithromycin-dihydrate/brand-names
- 41. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive salmonella infections. Clin Microbiol Rev. 2015;28(4):901–37. pmid:26180063
- 42. Lubell Y, Turner P, Ashley EA, White NJ. Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics. Trop Med Int Health. 2011;16(10):1192–205. pmid:21740488
- 43. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–33. pmid:20805405
- 44. Larramendy S, Gaultier A, Fournier J-P, Caillon J, Moret L, Beaudeau F. Local characteristics associated with higher prevalence of ESBL-producing Escherichia coli in community-acquired urinary tract infections: An observational, cross-sectional study. J Antimicrob Chemother. 2021;76(3):789–95. pmid:33351903
- 45. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev. 2005;18(4):657–86. pmid:16223952
- 46. Yaacoub S, Lanoy E, Hider-Mlynarz K, Saleh N, Maison P. Trend of antibiotic consumption and its association with influenza-like illnesses in France between 2004 and 2018. Eur J Public Health. 2021;31(6):1137–43. pmid:34534281
- 47. Chowdhury F, Bhuiya S, Abdul Aleem M, Shuvo TA, Mamun GMS, Kumar Ghosh P, et al. Decade-Long Trends in Antibiotic Prescriptions According to WHO AWaRe Classification Among Severe Acute Respiratory Infection Patients at Tertiary Hospitals in Bangladesh (2011-2020). Antibiotics (Basel). 2025;14(2):199. pmid:40001442
- 48. Patangia DV, Anthony Ryan C, Dempsey E, Paul Ross R, Stanton C. Impact of antibiotics on the human microbiome and consequences for host health. Microbiologyopen. 2022;11(1):e1260. pmid:35212478
- 49. Paul D, Das B. Gut microbiome in the emergence of antibiotic-resistant bacterial pathogens. Prog Mol Biol Transl Sci. 2022;192(1):1–31. pmid:36280316
- 50. Orubu ESF, Samad MA, Rahman MT, Zaman MH, Wirtz VJ. Mapping the Antimicrobial Supply Chain in Bangladesh: A Scoping-Review-Based Ecological Assessment Approach. Glob Health Sci Pract. 2021;9(3):532–47. pmid:34593580
- 51. Hsia Y, Lee BR, Versporten A, Yang Y, Bielicki J, Jackson C, et al. Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): An analysis of paediatric survey data from 56 countries. Lancet Glob Health. 2019;7(7):e861–71. pmid:31200888
- 52. Hassan MZ, Monjur MR, Biswas MAAJ, Chowdhury F, Kafi MAH, Braithwaite J, et al. Antibiotic use for acute respiratory infections among under-5 children in Bangladesh: A population-based survey. BMJ Glob Health. 2021;6(4):e004010. pmid:33903174
- 53. Havers FP, Hicks LA, Chung JR, Gaglani M, Murthy K, Zimmerman RK, et al. Outpatient antibiotic prescribing for acute respiratory infections during influenza seasons. JAMA Netw Open. 2018;1(2):e180243. pmid:30646067
- 54. Worldwide Antimicrobial Resistance National/International Network Group (WARNING) Collaborators. Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action. World J Emerg Surg. 2023;18(1):50. pmid:37845673
- 55. Budd E, Cramp E, Sharland M, Hand K, Howard P, Wilson P, et al. Adaptation of the WHO Essential Medicines List for national antibiotic stewardship policy in England: Being AWaRe. J Antimicrob Chemother. 2019;74(11):3384–9. pmid:31361000
- 56. Zanichelli V, Sharland M, Cappello B, Moja L, Getahun H, Pessoa-Silva C, et al. The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance. Bull World Health Org. 2023;101(04):290–6.
- 57. Ashiru-Oredope D, Garraghan F, Olaoye O, Krockow EM, Matuluko A, Nambatya W, et al. Development and Implementation of an Antimicrobial Stewardship Checklist in Sub-Saharan Africa: A Co-Creation Consensus Approach. Healthcare (Basel). 2022;10(9):1706. pmid:36141318
- 58. Bhuiya S, Chowdhury F. Syndemic approach to address the burden of antimicrobial resistance in Southeast Asia. Lancet Reg Health Southeast Asia. 2026;47:100747. pmid:41858406
- 59.
Directorate General of Health Services. National action plan: antimicrobial resistance containment in Bangladesh 2017–2022. Dhaka: Government of Bangladesh; 2017. https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/amr-spc-npm/nap-library/antimicrobial-resistance-containment-in-bangladesh-2017-2022.pdf?sfvrsn=bfa46b_3&download=true
- 60.
Directorate General of Health Services. National strategy and action plan for antimicrobial resistance containment in Bangladesh (2023-2028). Dhaka: Government of Bangladesh; 2023. https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/amr-spc-npm/nap-library/bangladesh_-nap-amr_23-28.pdf?sfvrsn=273364b9_1&download=true